Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk
D Parakkal, H Sifuentes, R Semer… - European journal of …, 2011 - journals.lww.com
Background Hepatosplenic T-cell lymphoma (HSTCL) is a rare, lethal disease generally
seen in young male patients with inflammatory bowel disease. The study of biologic and
immunomodulator naive patients in Crohn's disease (SONIC), advocates combining
infliximab with an immunomodulator in moderate-to-severe Crohn's disease. Unfortunately,
combined immunosuppression increases risk for HSTCL. We herein review all cases of
HSTCL reported to the Food and Drug Administration (FDA) in patients receiving TNF-α …
seen in young male patients with inflammatory bowel disease. The study of biologic and
immunomodulator naive patients in Crohn's disease (SONIC), advocates combining
infliximab with an immunomodulator in moderate-to-severe Crohn's disease. Unfortunately,
combined immunosuppression increases risk for HSTCL. We herein review all cases of
HSTCL reported to the Food and Drug Administration (FDA) in patients receiving TNF-α …
以上显示的是最相近的搜索结果。 查看全部搜索结果